WuXi Biologics (Cayman) Inc. provided unaudited consolidated earnings guidance for the year ended December 31, 2021. For the period, the company expected that the profit of the Company and the profit attributable to equity shareholders of the Company for the year ended December 31, 2021 will increase more than 105% and more than 98%, respectively, compared with those for the corresponding period of last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.6 HKD | -1.02% | -1.19% | -60.81% |
Jun. 19 | Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment | MT |
Jun. 13 | WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-60.81% | 6.23B | |
+15.47% | 122B | |
+19.76% | 113B | |
+6.93% | 22.84B | |
-18.73% | 20.72B | |
-16.10% | 16.51B | |
-12.90% | 16.39B | |
-43.53% | 15.83B | |
+1.92% | 13.49B | |
+77.56% | 11.67B |
- Stock Market
- Equities
- 2269 Stock
- News WuXi Biologics (Cayman) Inc.
- Wuxi Biologics Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021